Nephrology - Prova Education

1-16 of 21

MinuteCE®
Inside the 4 Hits: Targeting APRIL to Change the Course of IgAN
1.00 credit 9 episodes
- Richard Lafayette, MD, FACP
- Dana Rizk, MD
- Hong Zhang
- Suzuki Yusuke, MD, PhD
1.00 credit 9 episodes
The 4-Hit Hypothesis: Foundations of IgAN Pathogenesis
The 4-Hit Hypothesis: Foundations of IgAN Pathogenesis
MinuteCE®
The 4-Hit Hypothesis: Foundations of IgAN Pathogenesis
1.00 program credit
- Richard Lafayette, MD, FACP
1.00 program credit
APRIL Uncovered: An Upstream Driver in IgAN
APRIL Uncovered: An Upstream Driver in IgAN
MinuteCE®
APRIL Uncovered: An Upstream Driver in IgAN
1.00 program credit
- Dana Rizk, MD
- Hong Zhang
1.00 program credit
Mechanism-Based Targeting: Why APRIL Matters in IgAN
Mechanism-Based Targeting: Why APRIL Matters in IgAN
MinuteCE®
Mechanism-Based Targeting: Why APRIL Matters in IgAN
1.00 program credit
- Suzuki Yusuke, MD, PhD
- Dana Rizk, MD
1.00 program credit
IgAN SOC: Strengths and Limits
IgAN SOC: Strengths and Limits
MinuteCE®
IgAN SOC: Strengths and Limits
1.00 program credit
- Dana Rizk, MD
- Suzuki Yusuke, MD, PhD
1.00 program credit
Beyond RAASi and Approved Therapies: The Unmet Needs in IgAN
Beyond RAASi and Approved Therapies: The Unmet Needs in IgAN
MinuteCE®
Beyond RAASi and Approved Therapies: The Unmet Needs in IgAN
1.00 program credit
- Hong Zhang
1.00 program credit
Emerging Evidence: IgAN Disease-Modifying Agents
Emerging Evidence: IgAN Disease-Modifying Agents
MinuteCE®
Emerging Evidence: IgAN Disease-Modifying Agents
1.00 program credit
- Richard Lafayette, MD, FACP
- Hong Zhang
1.00 program credit
Emerging Therapies in IgAN: Who Could Benefit the Most?
Emerging Therapies in IgAN: Who Could Benefit the Most?
MinuteCE®
Emerging Therapies in IgAN: Who Could Benefit the Most?
1.00 program credit
- Richard Lafayette, MD, FACP
- Hong Zhang
1.00 program credit
Targeting Lower Proteinuria Levels: Shifting the Goalpost in IgAN
Targeting Lower Proteinuria Levels: Shifting the Goalpost in IgAN
MinuteCE®
Targeting Lower Proteinuria Levels: Shifting the Goalpost in IgAN
1.00 program credit
- Richard Lafayette, MD, FACP
- Suzuki Yusuke, MD, PhD
1.00 program credit
Translating Guidelines to Action in IgAN: Embracing a Simultaneous Dual-Concordant Approach
Translating Guidelines to Action in IgAN: Embracing a Simultaneous Dual-Concordant Approach
MinuteCE®
Translating Guidelines to Action in IgAN: Embracing a Simultaneous Dual-Concordant Approach
1.00 program credit
- Richard Lafayette, MD, FACP
- Suzuki Yusuke, MD, PhD
1.00 program credit
MinuteCE®
The Underestimated Consequences of Uncontrolled Gout: Renal and Cardiovascular Implications
- Richard Johnson, MD
- Abdul Abdellatif, MD, FASN
- John K. Botson, MD, RPh
- Brittany Weber, MD, PhD
Gout Beyond the Joints: What’s the Hidden Danger?
Gout Beyond the Joints: What’s the Hidden Danger?
MinuteCE®
Gout Beyond the Joints: What’s the Hidden Danger?
- Richard Johnson, MD
Is Gout Hiding in the Nephrology Clinic?
Is Gout Hiding in the Nephrology Clinic?
MinuteCE®
Is Gout Hiding in the Nephrology Clinic?
- Abdul Abdellatif, MD, FASN
- Richard Johnson, MD
Is Managing Gout in the Nephrology Clinic a Challenge?
Is Managing Gout in the Nephrology Clinic a Challenge?
MinuteCE®
Is Managing Gout in the Nephrology Clinic a Challenge?
- Richard Johnson, MD
- Abdul Abdellatif, MD, FASN
Center of the Target: Which Patients Are Most Likely to Develop Gout?
Center of the Target: Which Patients Are Most Likely to Develop Gout?
MinuteCE®
Center of the Target: Which Patients Are Most Likely to Develop Gout?
- Richard Johnson, MD
- Abdul Abdellatif, MD, FASN
Treat or Refer: Who Is Responsible for Managing Gout?
Treat or Refer: Who Is Responsible for Managing Gout?
MinuteCE®
Treat or Refer: Who Is Responsible for Managing Gout?
- John K. Botson, MD, RPh
- Abdul Abdellatif, MD, FASN

Prev
1
2
Next

1/2